Grifols SA
MAD:GRF

Watchlist Manager
Grifols SA Logo
Grifols SA
MAD:GRF
Watchlist
Price: 10.695 EUR -0.93%
Market Cap: 7.3B EUR
Section:
 

Relative Value

The Relative Value of one GRF stock under the Base Case scenario is 36.092 EUR. Compared to the current market price of 10.695 EUR, Grifols SA is Undervalued by 70%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

GRF Relative Value
Base Case
36.092 EUR
Undervaluation 70%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

1
P/S
P/S
Price to Sales
1
vs History
66
vs Industry
87
Median 3Y
1
Median 5Y
1.1
Industry
7.9
Forward
1
More Details
19.7
P/E
P/E
Price to Earnings
19.7
vs History
85
vs Industry
4
Median 3Y
37
Median 5Y
29.5
Industry
23.7
Forward
13.8
More Details
4.8
P/OCF
P/OCF
Price to OCF
4.8
vs History
71
vs Industry
14
Median 3Y
5.2
Median 5Y
18.2
Industry
22
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-11
Median 5Y
-6.6
Industry
23.8
More Details
1.4
P/B
P/B
Price to Book Value
1.4
vs History
47
vs Industry
58
Median 3Y
1.2
Median 5Y
1.4
Industry
3.3
More Details
2.1
EV/S
EV/S
Enterprise Value to Sales
2.1
vs History
71
vs Industry
67
Median 3Y
2.2
Median 5Y
2.3
Industry
8.3
Forward
2
More Details
5.3
EV/GP
EV/GP
Enterprise Value to Gross Profit
5.3
vs History
71
vs Industry
56
Median 3Y
5.6
Median 5Y
6
Industry
10.1
More Details
7.3
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
7.3
vs History
87
vs Industry
12
Median 3Y
12.4
Median 5Y
14.9
Industry
6.4
Forward
8.4
More Details
11.4
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
11.4
vs History
90
vs Industry
10
Median 3Y
16.1
Median 5Y
18.2
Industry
7
Forward
11.3
More Details
10.2
EV/OCF
EV/OCF
Enterprise Value to OCF
10.2
vs History
69
vs Industry
11
Median 3Y
10.5
Median 5Y
25.8
Industry
8.3
More Details
18.1
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
18.1
vs History
53
vs Industry
6
Median 3Y
-65.4
Median 5Y
19.5
Industry
6.5
More Details
0.8
EV/IC
EV/IC
Enterprise Value to IC
0.8
vs History
58
vs Industry
61
Median 3Y
0.8
Median 5Y
0.8
Industry
5.7
More Details

Multiples Across Competitors

GRF Competitors Multiples
Grifols SA Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
ES
Grifols SA
MAD:GRF
7.2B EUR 1 19.7 7.3 11.4
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 837 682.7 -160 825.5 -195 293.4 -193 064.9
US
Abbvie Inc
NYSE:ABBV
393.8B USD 6.6 167.7 16.3 23.1
US
Amgen Inc
NASDAQ:AMGN
174.5B USD 4.9 24.9 18 18
US
Gilead Sciences Inc
NASDAQ:GILD
150.9B USD 5.2 18.6 12.5 12.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
113.6B USD 9.7 30.9 22.7 23.7
US
Epizyme Inc
F:EPE
94.1B EUR 2 082 -531.3 -578.5 -563.1
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.8B USD 5.5 17.2 16.4 18.6
AU
CSL Ltd
ASX:CSL
84.8B AUD 3.6 18.7 12.6 15.7
NL
argenx SE
XBRU:ARGX
44.5B EUR 14.5 34.1 58.8 60.4
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
52.2B USD 16.3 1 198.1 157.3 190.8
P/S Multiple
Revenue Growth P/S to Growth
ES
Grifols SA
MAD:GRF
Average P/S: 3 076 348.3
1
6%
0.2
FR
Pharnext SCA
OTC:PNEXF
33 837 682.7
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.6
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.9
5%
1
US
Gilead Sciences Inc
NASDAQ:GILD
5.2
4%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.7
10%
1
US
E
Epizyme Inc
F:EPE
2 082
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.5
6%
0.9
AU
CSL Ltd
ASX:CSL
3.6
5%
0.7
NL
argenx SE
XBRU:ARGX
14.5
49%
0.3
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
16.3
46%
0.4
P/E Multiple
Earnings Growth PEG
ES
Grifols SA
MAD:GRF
Average P/E: 170
19.7
75%
0.3
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 825.5 N/A N/A
US
Abbvie Inc
NYSE:ABBV
167.7
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
24.9
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
18.6
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
30.9
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -531.3 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.2
9%
1.9
AU
CSL Ltd
ASX:CSL
18.7
11%
1.7
NL
argenx SE
XBRU:ARGX
34.1
40%
0.9
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 198.1
N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
ES
Grifols SA
MAD:GRF
Average EV/EBITDA: 35.8
7.3
12%
0.6
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -195 293.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.3
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18
11%
1.6
US
Gilead Sciences Inc
NASDAQ:GILD
12.5
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.7
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -578.5 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.4
11%
1.5
AU
CSL Ltd
ASX:CSL
12.6
8%
1.6
NL
argenx SE
XBRU:ARGX
58.8
807%
0.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
157.3
N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
ES
Grifols SA
MAD:GRF
Average EV/EBIT: 41.6
11.4
15%
0.8
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -193 064.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.1
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.5
12%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.7
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -563.1 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.6
13%
1.4
AU
CSL Ltd
ASX:CSL
15.7
11%
1.4
NL
argenx SE
XBRU:ARGX
60.4
N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
190.8
N/A N/A

See Also

Summary
GRF intrinsic value, competitors valuation, and company profile.
DCF Valuation
GRF stock valuation using Discount Cash Flow valuation method.
Relative Valuation
GRF stock valuation using valuation multiples.
Wall Street Estimates
GRF price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
GRF stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 304,000+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.